Edgar Filing: Hallal David - Form 4

Hallal David Form 4	l										
January 30, 2	2013										
FORM	TTIES A	ND EV		NCEC	OMMISSION	OMB APPROVAL					
UNITED STATES S				shington,			INGE C	OMMISSION	OMB Number:	3235-0287	
Check this box if no longer				CEC DI			LOW		Expires:	January 31, 2005	
subject to Section 1 Form 4 o Form 5 obligation may cont See Instru 1(b).	GES IN BENEFICIAL OWNERSHIP OF SECURITIES6(a) of the Securities Exchange Act of 1934, tility Holding Company Act of 1935 or Section westment Company Act of 1940					Estimated average burden hours per response 0.5					
(Print or Type I	Responses)										
Hallal David Sym AL			Symbol	EXION PHARMACEUTICALS				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	(First) (Middle)	3. Date of Earliest Transaction					Director		Owner	
C/O ALEXI PHARMAC KNOTTER	CEUTICALS, IN	C, 352	(Month/D 01/28/20	-				_X_ Officer (give below) EVP. Glob	title <u> </u>	er (specify l Ops	
				endment, Date Original nth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
		(7 :)						Person			
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)		Transaction Date 2A. Deemed Ionth/Day/Year) Execution Date, if any (Month/Day/Year)		3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or				Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock, par value \$.0001 per share	01/28/2013			Code V	Amount 632 <u>(1)</u>	(D)	Price \$ 94.5	(Instr. 3 and 4) 71,843	D		
Common Stock, par value \$.0001 per share	01/29/2013			S	512 <u>(1)</u>	D	\$ 94.32	71,331	D		

Edgar Filing: Hallal David - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Securi (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Hallal David						
C/O ALEXION PHARMACEUTICALS, INC			EVP. Global			
352 KNOTTER DRIVE			Commercial Ops			
CHESHIRE, CT 06410						
Cianaturaa						

Signatures

**Signature of

/s/ David Hallal

01/30/2013 Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.